Answers are grounded in this paper and cite their sources.
We previously identified a high level of molecular heterogeneity within mismatch repair deficiency (MMRd) colorectal cancer (CRC). Despite MMRd CRC being typically considered suitable for immunotherapy, only less than half of the metastatic CRC (mCRC) patients achieve complete remission. Thus, the search for identifying new therapeutic targets has become extremely urgent. The use of poly (ADP-ribose) polymerase inhibitor (PARPi) has revolutionized the treatment of homologous recombination deficiency (HRD) cancer; however, the HRD prevalence in CRC remains unclear. Here, we conducted an integrated analysis of genomic and methylation profiles from a cohort of Chinese MMRd CRC tumors. We successfully developed a novel DNA methylation signature that can effectively stratify MMRd tumors based on their HRD status. The findings suggest that within the MMRd CRC subgroup, more than half of tumors exhibit a concomitant HRD phenotype characterized by hypermethylation. The newly developed methylation-based classifier showed high performance in predicting HRD, offering a promising molecular tool for refining patient stratification. This study highlights the epigenetic heterogeneity of MMRd CRC and proposes a novel, methylation-based signature for identifying tumors with HRD, which may have implications for therapeutic strategies targeting DNA repair vulnerabilities.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: